[go: up one dir, main page]

WO2009041798A8 - Composiciones farmacéuticas que comprenden la combinación de un agente antiinflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa útiles para el control y tratamiento de la gota, artritis gotosa y enfermedades relacionadas. - Google Patents

Composiciones farmacéuticas que comprenden la combinación de un agente antiinflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa útiles para el control y tratamiento de la gota, artritis gotosa y enfermedades relacionadas. Download PDF

Info

Publication number
WO2009041798A8
WO2009041798A8 PCT/MX2008/000123 MX2008000123W WO2009041798A8 WO 2009041798 A8 WO2009041798 A8 WO 2009041798A8 MX 2008000123 W MX2008000123 W MX 2008000123W WO 2009041798 A8 WO2009041798 A8 WO 2009041798A8
Authority
WO
WIPO (PCT)
Prior art keywords
related diseases
nonsteroidal anti
xanthine oxidase
control
gouty arthritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/MX2008/000123
Other languages
English (en)
French (fr)
Other versions
WO2009041798A1 (es
Inventor
María Elena GARCÍA ARMENTA
Josefina Santos Murillo
Víctor Guillermo ÁLVAREZ OCHOA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Espinosa Abdala Leopoldo De Jesus
Original Assignee
Espinosa Abdala Leopoldo De Jesus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Espinosa Abdala Leopoldo De Jesus filed Critical Espinosa Abdala Leopoldo De Jesus
Priority to BRPI0817563 priority Critical patent/BRPI0817563A2/pt
Priority to EP08834122A priority patent/EP2210604A4/en
Priority to ARP080104183A priority patent/AR068560A1/es
Publication of WO2009041798A1 publication Critical patent/WO2009041798A1/es
Anticipated expiration legal-status Critical
Publication of WO2009041798A8 publication Critical patent/WO2009041798A8/es
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a diversas composiciones farmacéuticas compuestas por la combinación sinérgica de un agente antiinflamatorio no esteroideo, conocido como: Meloxicam o Celecoxib, y un agente inhibidor de la enzima xantino oxidasa, conocido como: Alopurinol, además de excipientes farmacéuticamente aceptables, mismos que se encuentran formulados en unidades de dosificación únicas para ser administradas por vía oral, las cuales están indicadas para el control y tratamiento de la Enfermedad gotosa o Gota, Artritis gotosa y otras patologías relacionadas. Dichas composiciones farmacéuticas proporcionan un mayor efecto terapéutico y una mayor rapidez de acción farmacológica en menor tiempo, logrando reducir el dolor, la inflamación y los niveles de uratos plasmáticos, además de conseguir la reducción de las dosis administradas, la reducción del riesgo de presentar complicaciones severas y la disminución del riesgo de manifestar efectos secundarios.
PCT/MX2008/000123 2007-09-26 2008-09-08 Composiciones farmacéuticas que comprenden la combinación de un agente antiinflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa útiles para el control y tratamiento de la gota, artritis gotosa y enfermedades relacionadas. Ceased WO2009041798A1 (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
BRPI0817563 BRPI0817563A2 (pt) 2007-09-26 2008-09-08 Composições farmacêuticas que compreendem a combinação de um agente antiinflamatório não esteróide e um agente inibidor da xantino oxidase úteis para o controle e tratamento da gota, artrite gotosas e enfermidades relacionadas
EP08834122A EP2210604A4 (en) 2007-09-26 2008-09-08 PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMBINATION OF A NON-STEROID ANTI-INFLAMMATORY AGENT AND A XANTHINE OXIDASE INHIBITING AGENT FOR USE IN THE CONTROL AND TREATMENT OF DROUGHT, DROPLED ARTHRITIS AND RELATED DISEASES
ARP080104183A AR068560A1 (es) 2007-09-26 2008-09-25 Composiciones farmaceuticas que comprenden la combinacion de un agente antiinflamatorio no esteroide y un agente inhibidor de la xantino oxidasa utiles para el control y tratamiento de la gota artritis gotosa y enfermedades relacionadas

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MXMX/A/2007/011927 2007-09-26
MX2007011927A MX2007011927A (es) 2007-09-26 2007-09-26 Composiciones farmaceuticas que comprenden la combinacion de un agente antiinflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa utiles para el control y tratamiento de la gota, artritis gotosa y enfermedades relacionadas.

Publications (2)

Publication Number Publication Date
WO2009041798A1 WO2009041798A1 (es) 2009-04-02
WO2009041798A8 true WO2009041798A8 (es) 2010-05-14

Family

ID=40511631

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MX2008/000123 Ceased WO2009041798A1 (es) 2007-09-26 2008-09-08 Composiciones farmacéuticas que comprenden la combinación de un agente antiinflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa útiles para el control y tratamiento de la gota, artritis gotosa y enfermedades relacionadas.

Country Status (10)

Country Link
EP (1) EP2210604A4 (es)
AR (1) AR068560A1 (es)
BR (1) BRPI0817563A2 (es)
CL (1) CL2008002884A1 (es)
CO (1) CO6270220A2 (es)
EC (1) ECSP10010054A (es)
MX (1) MX2007011927A (es)
PE (1) PE20091030A1 (es)
UY (1) UY31363A1 (es)
WO (1) WO2009041798A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008545627A (ja) 2005-05-09 2008-12-18 タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド 腎結石症を治療する方法
JP2010516691A (ja) * 2007-01-19 2010-05-20 タケダ ファーマシーティカルズ ノース アメリカ，アイエヌシー． 抗炎症剤及びキサンチン酸化還元酵素阻害剤を用いて痛風の突発を抑え、又はその数を減少させる方法
ES2532210T3 (es) 2010-09-10 2015-03-25 Takeda Pharmaceuticals U.S.A., Inc. Métodos para el tratamiento concomitante de teofilina y febuxostat
CN102973530B (zh) * 2012-12-14 2016-08-03 贵州信邦制药股份有限公司 一种非布索坦双层肠溶片剂及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010516691A (ja) * 2007-01-19 2010-05-20 タケダ ファーマシーティカルズ ノース アメリカ，アイエヌシー． 抗炎症剤及びキサンチン酸化還元酵素阻害剤を用いて痛風の突発を抑え、又はその数を減少させる方法

Also Published As

Publication number Publication date
CL2008002884A1 (es) 2009-03-20
BRPI0817563A2 (pt) 2015-03-31
UY31363A1 (es) 2009-03-31
EP2210604A1 (en) 2010-07-28
CO6270220A2 (es) 2011-04-20
EP2210604A4 (en) 2010-12-29
WO2009041798A1 (es) 2009-04-02
MX2007011927A (es) 2009-03-26
PE20091030A1 (es) 2009-08-06
AR068560A1 (es) 2009-11-18
ECSP10010054A (es) 2010-04-30

Similar Documents

Publication Publication Date Title
Gliozzi et al. The treatment of hyperuricemia
WO2005097125A3 (en) Methods and compositions for the treatment, prevention or management of diysfunctional sleep and dysfunctional sleep associated with disease
GEP20156281B (en) Orally administered corticosteroid compositions
WO2008040534A3 (en) Non-mucoadhesive film dosage forms
PT1175214E (pt) Composicoes de inibidor de ciclo-oxigenase-2 com um inicio rapido do seu efito terapeutico
WO2010121128A3 (en) Compositions and methods for treating or inhibiting liver injury
WO2008008474A3 (en) Compositions and methods for the treatment of chronic pain conditions
WO2009051840A3 (en) Compositions and methods for reducing hepatotoxicity associated with drug administration
WO2010116385A3 (en) Pharmaceutical compositions for alleviating unpleasant taste
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
MX2009004561A (es) Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor.
WO2009026473A3 (en) Stabilized therapeutic compositions and formulations
JP2012502047A5 (es)
BRPI0816798A2 (pt) composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
WO2007131070A3 (en) Compositions, dosage forms and methods of treating emesis
WO2009041798A8 (es) Composiciones farmacéuticas que comprenden la combinación de un agente antiinflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa útiles para el control y tratamiento de la gota, artritis gotosa y enfermedades relacionadas.
WO2008012796A3 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
WO2007145863A3 (en) Sustained release formulation of naltrexone
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
WO2006115770A3 (en) Orally disintegrating pharmaceutical tablet formulations of olanzapine
MX384760B (es) Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático.
MX2010013484A (es) Formulaciones en dosis unitaria de ketorolaco para administración intra-nasal.
WO2005120518A3 (en) Use of atp analogues for treatment of cardiovascular diseases
WO2009041799A8 (es) Composición farmacéutica compuesta por la combinación de sulfato de condroitina y diacereina y su uso en el tratamiento de la osteoartritis y enfermedades relacionadas.
WO2009022893A8 (es) Composición farmacéutica que comprende la combinación de un agente antimicrobiano y un agente inhibidor selectivo de la enzima encefalinasa, indicada para el control y tratamiento de la diarrea aguda de origen bacteriano

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08834122

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10036286

Country of ref document: CO

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008834122

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: PI0817563

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100326